ArticlePloS one2012
An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Fusion Inhibition of Zika Virus Entry by a Teicoplanin Pseudoaglycone Derivative with Broad Antiviral Activity.Pharmaceutics · 2026Article
- Repositioning of Antibiotics in the Treatment of Viral Infections.Current microbiology · 2024Review
- Article
- Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Reprogramming of the Antibacterial Drug Vancomycin Results in Potent Antiviral Agents Devoid of Antibacterial Activity.Pharmaceuticals (Basel, Switzerland) · 2020Article
- TLR2 on blood monocytes senses dengue virus infection and its expression correlates with disease pathogenesis.Nature communications · 2020Article
- COVID-19 Therapeutic Options Under Investigation.Frontiers in pharmacology · 2020Review
- Glycopeptides as Potential Interventions for COVID-19.Biologics : targets & therapy · 2020Review
- Battling COVID-19: using old weapons for a new enemy.Tropical diseases, travel medicine and vaccines · 2020Review
- The altered gut virome community in rhesus monkeys is correlated with the gut bacterial microbiome and associated metabolites.Virology journal · 2019Article
- Hydrophobic Derivatives of Glycopeptide Antibiotics as Inhibitors of Protein Kinases.Biochemistry. Biokhimiia · 2018Article
- Review
- Oral Antibiotic Treatment of Mice Exacerbates the Disease Severity of Multiple Flavivirus Infections.Cell reports · 2018Article
- The citrus flavanone naringenin impairs dengue virus replication in human cells.Scientific reports · 2017Article
- Fighting viruses with antibiotics: an overlooked path.International journal of antimicrobial agents · 2016Article
- Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).The Journal of biological chemistry · 2016Article
- Teicoplanin inhibits Ebola pseudovirus infection in cell culture.Antiviral research · 2016Article
- Quinic acid derivatives inhibit dengue virus replication in vitro.Virology journal · 2015Article
- Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.Journal of neurovirology · 2014Review
- Progress in the identification of dengue virus entry/fusion inhibitors.BioMed research international · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an urgent need for potent inhibitors of dengue virus (DENV) replication for the treatment and/or prophylaxis of infections with this virus. We here report on an aglycon analogue of the antibiotic teicoplanin (code name LCTA-949) that inhibits DENV-induced cytopathic effect (CPE) in a dose-dependent manner. Virus infection was completely inhibited at concentrations that had no adverse effect on the host cells. These findings were corroborated by quantification of viral RNA levels in culture supernatant. Antiviral activity was also observed against other flaviviruses such as the yellow fever virus and the tick-borne encephalitis virus (TBEV). In particular, potent antiviral activity was observed against TBEV. Time-of-drug-addition experiments indicated that LCTA-949 inhibits an early stage in the DENV replication cycle; however, a virucidal effect was excluded. This observation was corroborated by the fact that LCTA-949 lacks activity on DENV subgenomic replicon (that does not encode structural proteins) replication. Using a microsopy-based binding and fusion assay employing DiD-labeled viruses, it was shown that LCTA-949 targets the early stage (binding/entry) of the infection. Moreover, LCTA-949 efficiently inhibits infectivity of DENV particles pre-opsonized with antibodies, thus potentially also inhibiting antibody-dependent enhancement (ADE). In conclusion, LCTA-949 exerts in vitro activity against several flaviviruses and does so (as shown for DENV) by interfering with an early step in the viral replication cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.